MRTX - ミラティ・セラピュ―ティックス (Mirati Therapeutics Inc.) ミラティ・セラピュ―ティックス

 MRTXのチャート


 MRTXの企業情報

symbol MRTx
会社名 Mirati Therapeutics Inc (ミラティ・セラピュ―ティックス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Mirati Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of targeted oncology products. The Company's clinical pipeline consists of three product candidates: MGCD265 MGCD516 and mocetinostat. MGCD265 and MGCD516 are orally-bioavailable spectrum-selective kinase inhibitors. Both MGCD265 and MGCD516 are in development to treat patients with non-small cell lung cancer (NSCLC) and other solid tumors. MGCD265 is in Phase Ib clinical development and MGCD516 is in the dose escalation phase of Phase I clinical development. Mocetinostat is an orally-bioavailable spectrum-selective histone deacetylase (HDAC) inhibitor which is in Phase II development. Mocetinostat is being developed for the second line treatment of patients with bladder cancer and non-hodgkins lymphoma (NHL) specifically focusing on diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL).   ミラティ・セラピュ―ティックスは、臨床期の米国バイオ医薬品企業。一部の癌患者の治療のため医薬品開発に焦点を当てる。主な製品は、「MGCD265」、「MGCD516」と「mocetinostat」。非小細胞肺癌、頭頸部の扁平上皮癌、および他の固形腫瘍、骨髄異形成症候群を有する患者を治療するために製品を開発する。   Mirati Therapeutics is a late-stage biotechnology company whose mission is to discover, design and deliver breakthrough therapies to transform the lives of patients with cancer and their loved ones. The company is relentlessly focused on bringing forward therapies that address areas of high unmet need, including lung cancer, and advancing a pipeline of novel therapeutics targeting the genetic and immunological drivers of cancer. Mirati is using its scientific expertise to develop novel solutions in two registration-enabling programs: adagrasib (MRTX849), an investigational small molecule, potent and selective KRAS G12C inhibitor, as monotherapy and in combination with other agents, and sitravatinib, an investigational spectrum-selective inhibitor of receptor tyrosine kinases in combination with checkpoint inhibitor therapies. Mirati is also advancing its differentiated preclinical portfolio, including MRTX1133, an investigational KRAS G12D inhibitor, and other oncology discovery programs. Unified for patients, Mirati's vision is to unlock the science behind the promise of a life beyond cancer.
本社所在地 9393 Towne Centre Drive Suite 200 San Diego CA 92121 USA
代表者氏名 Rodney W. Lappe ロドニー・W・ラッペ
代表者役職名 Executive Independent Chairman of the Board
電話番号 +1 858-332-3410
設立年月日 41365
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 51人
url www.mirati.com
nasdaq_url https://www.nasdaq.com/symbol/mrtx
adr_tso
EBITDA EBITDA(百万ドル) -78.67100
終値(lastsale) 44.38
時価総額(marketcap) 1436071738.92
時価総額 時価総額(百万ドル) 1294.665
売上高 売上高(百万ドル) 9.46700
企業価値(EV) 企業価値(EV)(百万ドル) 134.481
当期純利益 当期純利益(百万ドル) -76.82300
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Mirati Therapeutics Inc revenues increased from $0K to $9.5M. Net loss increased 18% to $42.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and develpment balancng value increase of 55% to $34.9M (expense) Stock-based Compensation in SGA increase from $2.1M to $4.3M (expense).

 MRTXのテクニカル分析


 MRTXのニュース

   Buy - Head-To-Head Review: Orphazyme A/S and Mirati Therapeutics  2021/12/20 09:27:06 Business Mag
Orphazyme A/S and Mirati Therapeutics are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their
   Head-To-Head Review: Orphazyme A/S (NASDAQ:ORPH) and Mirati Therapeutics (NASDAQ:MRTX)  2021/12/20 09:26:46 ETF Daily News
Orphazyme A/S (NASDAQ:ORPH) and Mirati Therapeutics (NASDAQ:MRTX) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, earnings, risk, dividends, profitability and analyst recommendations. Volatility and Risk Orphazyme A/S has a beta of 1.46, meaning that its share price is [] The post Head-To-Head Review: Orphazyme A/S (NASDAQ:ORPH) and Mirati Therapeutics (NASDAQ:MRTX) appeared first on ETF Daily News .
   A Bullish 2021 Outlook For Mirati Therapeutics Inc. (NASDAQ: MRTX) Shares  2021/12/18 16:00:00 Stocks Register
Mirati Therapeutics Inc. (NASDAQ:MRTX) shares, rose in value on Friday, 12/17/21, with the stock price up by 6.45% to the previous days close as strong demand from buyers drove the stock to $144.96. Actively observing the price movement in the last trading, the stock closed the session at $136.18, falling within a range of $131.07 A Bullish 2021 Outlook For Mirati Therapeutics Inc. (NASDAQ: MRTX) Shares Read More »
   Glenview Capital Management Buys Willis Towers Watson PLC, Uber Technologies Inc, Baxter ...  2021/12/14 04:38:02 GuruFocus
Related Stocks: UBER , BAX , GPN , APTV , CHNG , DD , WLTW , EHC , CCCS , OGN , MRTX , VIAC , DXC , ANTM , BHVN , FB , HCA , WBA , AMZN , IQV , MDT , BABA , DGNR ,
   Inv Corp Small Cap Growth Buys Zuora Inc, Ollie''s Bargain Outlet Holdings Inc, Sonic Automotive ...  2021/12/08 23:38:03 GuruFocus
Related Stocks: SAH , BLMN , FSS , NOG , FRPT , SPNE , ZUO , OLLI , RCII , RDFN , MRTX , LAD , CLDR , PLUG , RUN ,
   Squarepoint Ops LLC Takes $1.67 Million Position in Mirati Therapeutics, Inc. (NASDAQ:MRTX)  2021/11/08 13:16:42 Dakota Financial News
Squarepoint Ops LLC acquired a new stake in shares of Mirati Therapeutics, Inc. (NASDAQ:MRTX) in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 10,330 shares of the biotechnology company’s stock, valued at approximately $1,669,000. Several other institutional investors and hedge funds have also modified […]
   Given A -52.19% Drop From High, Can Mirati Therapeutics Inc. (NASDAQ: MRTX) Quickly Recover?  2021/11/06 15:30:00 Marketing Sentinel
During the last session, Mirati Therapeutics Inc. (NASDAQ:MRTX)s traded shares were 0.39 million, with the beta value of the company hitting 1.27. At the end of the trading day, the stocks price was $163.89, reflecting an intraday loss of -2.11% or -$3.53. The 52-week high for the MRTX share is $249.42, that puts it down Given A -52.19% Drop From High, Can Mirati Therapeutics Inc. (NASDAQ: MRTX) Quickly Recover? Read More »
   SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mirati Therapeutics, Inc. - MRTX  2021/11/04 08:41:00 PR Newswire
NEW YORK, Nov. 4, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Mirati Therapeutics, Inc. ("Mirati" or the "Company") (NASDAQ: MRTX). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The…
   Mirati Therapeutics (NASDAQ:MRTX) Shares Gap Down to $189.02  2021/11/03 09:04:45 Transcript Daily
Shares of Mirati Therapeutics, Inc. (NASDAQ:MRTX) gapped down before the market opened on Monday . The stock had previously closed at $189.02, but opened at $177.28. Mirati Therapeutics shares last traded at $167.89, with a volume of 10,128 shares trading hands. Several brokerages recently weighed in on MRTX. Oppenheimer raised their target price on Mirati []
   ABVC BioPharma, ANI Pharmaceuticals leads healthcare gainers; Centessa Pharmaceuticals, Mirati Therapeutics among major losers  2021/11/01 15:03:43 Seeking Alpha
   Mirati Therapeutics to Present Late-Breaking Data That Advance the Understanding of Synthetic Lethal PRMT5 Inhibitors in MTAP-Deleted Cancers at AACR 2021  2021/03/10 21:39:00 PR Newswire
SAN DIEGO, March 10, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a late-stage targeted oncology company, today announced it will present initial preclinical data on the Company's synthetic lethal PRMT5 inhibitor during a late-breaking minisymposium at the American…
   Oppenheimer Stick to Their Buy Rating for Mirati Therapeutics By Investing.com  2021/03/01 00:45:01 Investing.com
Oppenheimer Stick to Their Buy Rating for Mirati Therapeutics
   Mirati Therapeutics (NASDAQ:MRTX) Announces Quarterly Earnings Results  2021/02/26 21:32:53 Transcript Daily
Mirati Therapeutics (NASDAQ:MRTX) announced its quarterly earnings data on Thursday. The biotechnology company reported ($2.08) EPS for the quarter, topping the Zacks’ consensus estimate of ($2.23) by $0.15, MarketWatch Earnings reports. Mirati Therapeutics stock traded up $5.24 during mid-day trading on Friday, hitting $200.84. 23,535 shares of the company’s stock traded hands, compared to its […]
   Mirati Therapeutics Reports Fourth Quarter And Full-Year 2020 Financial Results And Recent Corporate Updates  2021/02/25 21:15:00 PR Newswire
SAN DIEGO, Feb. 25, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a late-stage targeted oncology company, today reported financial results for the fourth quarter and full year of 2020, which reflect the company's progress across its clinical and discovery pipeline and…
   Global Advanced Urotheilal carcinoma Pipeline Insight Report 2021 Featuring Rogaratininb (Bayer) & Sitravatinib (Mirati Therapeutics) - ResearchAndMarkets.com  2021/02/23 12:36:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Advanced Urotheilal carcinoma - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering. This "Advanced Urothelial Carcinoma - Pipeline Insight, 2021," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Advanced Urothelial Carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and non clinical stage products. It also covers the therapeutics assessment by product typ

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ミラティ・セラピュ―ティックス MRTX Mirati Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)